Esperion Therapeutics Inc... (ESPR)
Esperion Therapeutics Statistics
Share Statistics
Esperion Therapeutics has 197.03M shares outstanding. The number of shares has increased by 15.62% in one year.
| Shares Outstanding | 197.03M |
| Shares Change (YoY) | 15.62% |
| Shares Change (QoQ) | 0.41% |
| Owned by Institutions (%) | 66.33% |
| Shares Floating | 195.04M |
| Failed to Deliver (FTD) Shares | 113.38K |
| FTD / Avg. Volume | 1.97% |
Short Selling Information
The latest short interest is 33.98M, so 17.24% of the outstanding shares have been sold short.
| Short Interest | 33.98M |
| Short % of Shares Out | 17.24% |
| Short % of Float | 17.42% |
| Short Ratio (days to cover) | 7.21 |
Valuation Ratios
The PE ratio is -1.47 and the forward PE ratio is -18.06. Esperion Therapeutics 's PEG ratio is 0.03.
| PE Ratio | -1.47 |
| Forward PE | -18.06 |
| PS Ratio | 2.65 |
| Forward PS | 0.7 |
| PB Ratio | -0.68 |
| P/FCF Ratio | -2.28 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Esperion Therapeutics Inc. has an Enterprise Value (EV) of 766.99M.
| EV / Earnings | -3.67 |
| EV / Sales | 6.59 |
| EV / EBITDA | -5.11 |
| EV / EBIT | -4.93 |
| EV / FCF | -5.66 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of -1.19.
| Current Ratio | 1.29 |
| Quick Ratio | 0.87 |
| Debt / Equity | -1.19 |
| Total Debt / Capitalization | 629.35 |
| Cash Flow / Debt | -0.25 |
| Interest Coverage | -2.64 |
Financial Efficiency
Return on equity (ROE) is 0.46% and return on capital (ROIC) is -180.99%.
| Return on Equity (ROE) | 0.46% |
| Return on Assets (ROA) | -1.02% |
| Return on Capital (ROIC) | -180.99% |
| Revenue Per Employee | 484.73K |
| Profits Per Employee | -871.87K |
| Employee Count | 240 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -29.28% in the last 52 weeks. The beta is 1.01, so Esperion Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -29.28% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 2.19 |
| Relative Strength Index (RSI) | 40.25 |
| Average Volume (20 Days) | 5.75M |
Income Statement
In the last 12 months, Esperion Therapeutics had revenue of 116.33M and earned -209.25M in profits. Earnings per share was -2.03.
| Revenue | 116.33M |
| Gross Profit | 73.07M |
| Operating Income | -155.56M |
| Net Income | -209.25M |
| EBITDA | -150.11M |
| EBIT | -155.56M |
| Earnings Per Share (EPS) | -2.03 |
Balance Sheet
The company has 82.25M in cash and 540.95M in debt, giving a net cash position of -458.7M.
| Cash & Cash Equivalents | 82.25M |
| Total Debt | 540.95M |
| Net Cash | -458.7M |
| Retained Earnings | -1.55B |
| Total Assets | 314.11M |
| Working Capital | 141.68M |
Cash Flow
In the last 12 months, operating cash flow was -135.49M and capital expenditures 0, giving a free cash flow of -135.49M.
| Operating Cash Flow | -135.49M |
| Capital Expenditures | 0 |
| Free Cash Flow | -135.49M |
| FCF Per Share | -1.31 |
Margins
Gross margin is 62.81%, with operating and profit margins of -133.72% and -179.87%.
| Gross Margin | 62.81% |
| Operating Margin | -133.72% |
| Pretax Margin | -179.87% |
| Profit Margin | -179.87% |
| EBITDA Margin | -129.03% |
| EBIT Margin | -133.72% |
| FCF Margin | -116.46% |
Dividends & Yields
ESPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -109.14% |
| FCF Yield | -36.97% |
Analyst Forecast
The average price target for ESPR is $4, which is 115.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 115.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -5.54 |
| Piotroski F-Score | 4 |